Survivors for Solutions Opposes the Most Favored Nation Policy

Despite its name, the “Most Favored Nation” (MFN) drug pricing policy would do nothing to favor American patients. This policy would tie U.S. drug prices to those in other countries, where government-set prices lead to reduced or nonexistent access for patients in need. Policymakers who want to keep America the leader in innovation and protect patients must reject this policy.

  • The countries to which MFN seeks to tie U.S. prices often use socialist pricing mechanisms to set prices artificially. They also use discriminatory valuation tools like the quality-adjusted life year (QALY) that de-prioritize and devalue care for the sickest patients. Any efforts to fix our prices to these countries essentially import this system, which is cruel and un-American.

  • Patients in these countries have access to fewer drugs—and get access to them later—than patients in America. When MFN causes these same results in the U.S. market, and foreign patients cannot turn to us, where will they go?

  • Prices dependent on foreign governments, not the free market, will decrease certainty in the ability of medical innovators to generate returns on the substantial investments that go into creating a new treatment or cure. This will remove the incentive for innovation, reducing the number of new drugs brought to market in America and worldwide.

Policymakers must reconsider efforts to implement MFN pricing on American pharmaceuticals to ensure every patient has access to a treatment or cure for their condition.

Learn more about this policy from Survivors for Solutions’ Founder and Chairman, John Czwartacki: Most Favored Nation Has No Place in U.S. Healthcare  & America Last? How Foreign Price Controls Threaten U.S. Patients.

More opposition resources: